Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medicoeconomic Analysis of the Towards the Lowest Efficacious Dose Trial

被引：0
|
作者：
Kedra, Joanna [1 ,2 ]
Granger, Benjamin [2 ,3 ]
El Houari, Lina [4 ]
Tubach, Florence [5 ]
Fautrel, Bruno [6 ]
机构：
[1] Sorbonne Univ, IPLESP, Paris, France
[2] Hop La Pitie Salpetriere, Paris, France
[3] Sorbonne Univ, INSERM, Paris, France
[4] Inst Pierre Louis Epidemiol & Sante Publ, Paris, France
[5] APHP, Ctr Pharm Epidemiol, Paris, France
[6] Sorbonne Univ, APHP, Paris, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2169
引用
收藏
页码：4285 / 4286
页数：2
相关论文
共 50 条
  • [21] Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial
    Sanmarti, Raimon
    Veale, Douglas J.
    Martin-Mola, Emilio
    Escudero-Contreras, Alejandro
    Gonzalez, Carlos
    Ercole, Liliana
    Alonso, Rocio
    Fonseca, Joao E.
    Alcaniz, Cristina
    Maria Alvaro-Gracia, Jose
    Balsa, Alejandro
    Luis de Pablos, Jose
    Diaz Miguel, Consuelo
    Manuel Rodriguez, Jose
    Alves, Jose
    Aurrecoechea, Elena
    Calvo, Jaime
    Belzunegui, Joaquin
    Blanco, Francisco
    Caliz, Rafael
    Calvo, Javier
    Roman Ivorra, Jose
    Canhao, Helena
    Santos, Helena
    Chamizo, Eugenio
    del Pino, Javier
    Delgado, Concepcion
    Diaz, Cesar
    Fernandez Nebro, Antonio
    Fraser, Alexander
    Gomez, Antonio
    Hernandez, Blanca
    Navarro, Federico
    Pov-Marras, Juan
    Moreno, Juan
    Perez Venegas, Jose
    Pombo, Manuel
    Riera, Elena
    Rosas, Antonio
    Ryan, John
    Santos, Jose
    Santos, Maria
    Tornero, Jesus
    Victor Tovar, Juan
    Ucar, Eduardo
    Vasconcelos, Carlos
    Veiga, Raul
    Vela, Paloma
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (10) : 1616 - 1625
  • [22] A COST-UTILITY ANALYSIS OF MISOPROSTOL PROPHYLAXIS FOR RHEUMATOID-ARTHRITIS PATIENTS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    GABRIEL, SE
    CAMPION, ME
    OFALLON, WM
    ARTHRITIS AND RHEUMATISM, 1994, 37 (03): : 333 - 341
  • [23] Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial
    Vanier, Antoine
    Mariette, Xavier
    Tubach, Florence
    Fautrel, Bruno
    VALUE IN HEALTH, 2017, 20 (04) : 577 - 585
  • [24] Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
    van Mulligen, Elise
    Weel, Angelique E.
    Kuijper, Tjallingius Martijn
    Denissen, N. H. A. M.
    Gerards, Andreas H.
    de Jager, Mike H.
    Lam-Tse, Wai-Kwan
    Hazes, J. M.
    van der Helm-van Mil, Annette
    de Jong, Pascal Hendrik Pieter
    Luime, Jolanda J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) : 1550 - 1556
  • [25] THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATING RHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITY ANALYSIS AND BUDGET IMPACT ANALYSIS
    Li, C.
    Chou, P.
    Chang, C.
    Fann, C. S.
    VALUE IN HEALTH, 2016, 19 (07) : A915 - A915
  • [26] Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
    van Mulligen, Elise
    Weel, Angelique
    Hazes, Mieke
    van der Helm-van Mil, Annette
    de Jong, Pascal
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] TWO-YEAR COST-EFFECTIVENESS BETWEEN TWO GRADUAL TAPERING STRATEGIES IN RHEUMATOID ARTHRITIS: COST-UTILITY ANALYSIS OF THE TARA TRIAL
    Van Mulligen, E.
    Weel, A.
    Kuijper, M.
    Hazes, J.
    De Jong, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 175 - 175
  • [28] Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
    Tzanetakos, C.
    Tzioufas, A.
    Goules, A.
    Kourlaba, G.
    Theodoratou, T.
    Christou, P.
    Maniadakis, N.
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (09) : 1441 - 1452
  • [29] Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
    C. Tzanetakos
    A. Tzioufas
    A. Goules
    G. Kourlaba
    T. Theodoratou
    P. Christou
    N. Maniadakis
    Rheumatology International, 2017, 37 : 1441 - 1452
  • [30] Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
    Tanaka, Yoshiya
    Oba, Koji
    Koike, Takao
    Miyasaka, Nobuyuki
    Mimori, Tsuneyo
    Takeuchi, Tsutomu
    Hirata, Shintaro
    Tanaka, Eiichi
    Yasuoka, Hidekata
    Kaneko, Yuko
    Murakami, Kosaku
    Koga, Tomohiro
    Nakano, Kazuhisa
    Amano, Koichi
    Ushio, Kazuyasu
    Atsumi, Tatsuya
    Inoo, Masayuki
    Hatta, Kazuhiro
    Mizuki, Shinichi
    Nagaoka, Shohei
    Tsunoda, Shinichiro
    Dobashi, Hiroaki
    Horie, Nao
    Sato, Norihiro
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345